Clinical trials: Human Volunteers
Healthy Volunteers
Evaluation of the Effects of DracoBelle Nu in Skin Health After Oral Intake
The goal of this clinical trial is to study the effects of DracoBelleTM Nu in different skin parameters associated with age. Volunteers will be asked to take either placebo of DracoBelleTM Nu capsules once a day by oral intake…
- Trial name
- NCT06059534
- Testing
- Dietary supplementation with DracoBelleTM Nu.
- Where
- Spain
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Bionos Biotech S.L.
Healthy
Bioequivalence Study of Torrent Pharmaceuticals Ltd's Bioequivalence Study of Torrent Pharmaceuticals Ltd's Quetiapine Tablets Under Fed Conditions
Objective: Primary objective of the present study was to compare the single dose bioequivalence of Torrent's Quetiapine Fumarate Tablets 1 × 25 mg. Dosing periods of the study were separated by a washout period of 7 days.
- Trial name
- NCT01634399
- Testing
- Torrent's Quetiapine Fumarate Tablets
- Where
- India
- Volunteers
- healthy volunteers welcome
- Sponsor
- Torrent Pharmaceuticals Limited
Sensitivity, Contact
Sensitization Study of ATx201 in Healthy Volunteers
This is a Phase I, single-site study to evaluate the sensitization potential of topically applied ATx201 GEL, 2% and 4%, along with a placebo control, in healthy human subjects.
- Trial name
- NCT03375957
- Testing
- ATx201
- Where
- United States
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- UNION therapeutics
Abdominal Pain/ Discomfort, Slightly Constipation
Effect of Perilla Extract on Improvement on Gastrointestinal Discomfort
In the current study the effects of proprietary Perilla frutescens leaf extract in comparison to Maltodextrin, a fully digestible carbohydrate (placebo control), on gastrointestinal discomfort and bowel function were…
- Trial name
- NCT01931930
- Testing
- Perilla extract, Maltodextrin
- Where
- Germany
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Amino Up Chemicals Co., Ltd.
Healthy
Bioequivalence Study of Torrent Pharmaceuticals Ltd's Pioglitazone Hydrochloride Tablets Under Fasting Conditions
Objective: subjects to compare the single dose bioavailability of Torrent's Pioglitazone Hydrochloride Tablets 1 × 45 mg and Actos® Tablets 1 × 45 mg of Takeda Pharmaceuticals America, Inc.
- Trial name
- NCT01797666
- Testing
- Torrent's Pioglitazone Hydrochloride Tablets 45 mg
- Where
- India
- Volunteers
- healthy volunteers welcome
- Sponsor
- Torrent Pharmaceuticals Limited
Basal Cell Carcinoma
Placebo Microneedles in Healthy Volunteers (Part I) and Efficacy/Safety of Doxorubicin Microneedles in Basal Cell Cancer Subjects (Part II)
Part I is designed as a study of P-MNA application in healthy human volunteers. The goal of Part I is to determine several factors possibly affecting the rate and extent of microneedle array dissolution, such as anatomic…
- Trial name
- NCT04928222
- Testing
- Doxorubicin-containing MNA
- Where
- 2 sites in United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- SkinJect, Inc.
Healthy Volunteer
A Human Tick Kill Study to Investigate the Safety, Tolerability, and Whole Blood Concentration of TP-05
This is a Phase 2a, randomized, double-blind, proof-of-concept, single-center study evaluating the safety, tolerability, and whole blood concentration of TP-05 (lotilaner) in the killing of ticks after they have attached to human…
- Trial name
- NCT05387083
- Testing
- Low Dose TP-05, High Dose TP-05
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Tarsus Pharmaceuticals, Inc.
Healthy Male Volunteers
A Study to Test the Safety, Pharmacokinetics, and Pharmacodynamics of Single Ascending Intravenous Doses of UCB0107 in Healthy Male Subjects
The purpose of the study is to evaluate the safety and tolerability of single ascending doses of UCB0107 administered by intravenous (iv) infusion in healthy male subjects.
- Trial name
- NCT03464227
- Testing
- UCB0107
- Where
- Germany
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- UCB Biopharma S.P.R.L.
Breast Cancer
A Dose-Finding Study of Subcutaneous Herceptin (Trastuzumab) in Healthy Male Volunteers and Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Females
This two-part study is designed to select the subcutaneous (SC) dose of Herceptin that results in comparable exposure to intravenous (IV) Herceptin in healthy male participants and in HER2-positive female participants.
- Trial name
- NCT00800436
- Testing
- Herceptin
- Where
- 3 sites in Australia, New Zealand
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Inflammatory Bowel Disease (IBD)
A Phase 1 Study of PVT401 in Healthy Subjects
The goal of this clinical trial is to learn what happens to PVT401 when it enters the human body and how it affects the immune system.
- Trial name
- NCT07423000
- Testing
- PVT401, Normal Saline (0.9% NaCl)
- Where
- Australia
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Parvus Therapeutics, Inc.
Anthrax
Safety and Pharmacokinetics Study of Human Monoclonal Antibody (AVP-21D9)
Primary: To compare the safety profile of a single intravenous administration of AVP-21D9 as compared with Placebo Secondary: To evaluate the pharmacokinetics (PK) of a single intravenous administration of AVP-21D9 To evaluate…
- Trial name
- NCT01202695
- Testing
- AVP-21D9
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Emergent BioSolutions
Diabetes Mellitus
Safety and Tolerability of GX-G6 in Healthy Male Subjects
This study is a single-center, double-blind, placebo-controlled, phase I study with healthy male subjects receiving ascending single s.c. doses of GX-G6
- Trial name
- NCT03651466
- Testing
- Gx-G6
- Where
- Germany
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Genexine, Inc.
Healthy Volunteers, Healthy
A Study Designed to Compare the Safety and Pharmacokinetics of Intravenously Administered Superoxide Dismutase Mimetic GC4711 and GC4419 in Healthy Volunteers
The study will be a double-blind, randomized, crossover, single-dose assessment of IV-administered GC4711 compared to GC4419 in healthy volunteers.
- Trial name
- NCT03194139
- Testing
- GC4711 30 mg IV, GC4711 50 mg IV, GC4419 45 mg IV
- Where
- Australia
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Galera Therapeutics, Inc.
Growth Hormone Deficiency
Pharmacokinetics and Pharmacodynamics of Long Acting Human Growth Hormone (hGH) Product (MOD-4023) in Healthy Caucasian and Japanese Volunteers
The study is a Phase 1, randomized, double-blind, vehicle-controlled, single-dose, three dose levels study in healthy Caucasian and Japanese male volunteers.
- Trial name
- NCT02418767
- Testing
- MOD-4023
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- OPKO Health, Inc.
Gaucher Disease
Phase I Single Dose-Escalation Safety Study of Human Glucocerebrosidase (prGCD)
Gaucher disease, the most prevalent lysosomal storage disorder, is caused by mutations in the human glucocerebrosidase gene (GCD)leading to reduced activity of the lysosomal enzyme glucocerebrosidase and thereby to the…
- Trial name
- NCT00258778
- Testing
- Human Glucocerebrosidase (prGCD)
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Protalix
Haemostasis, Healthy
Efficacy of Activated Recombinant Human Factor VII in Healthy Volunteers Treated for Punch Biopsy Mediated Bleeding
This trial is conducted in the United States of the America (USA). The aim of this trial is to evaluate the effectiveness of activated recombinant human factor VII to mitigate experimentally-induced bleeding in healthy volunteers…
- Trial name
- NCT01561950
- Testing
- eptacog alfa (activated), clopidogrel
- Where
- United States
- Volunteers
- 91 people
- Sponsor
- Novo Nordisk A/S
Healthy Volunteers
Phase 1 Study of IPG1094 Safety, Tolerability, and PK in Healthy Participants
This is a phase 1, first-in-human, randomized, double-blind, placebo-controlled, single dose escalation study to evaluate the safety, tolerability, and PK of single dose orally administered IPG1094 in healthy adult participants.
- Trial name
- NCT05112159
- Testing
- IPG1094 300 mg SAD, IPG1094 600 mg SAD, IPG1094 900 mg SAD
- Where
- Australia
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Nanjing Immunophage Biotech Co., Ltd
Healthy Volunteer
AZD8529 Single Ascending Dose Study
This is a study to evaluate safety, tolerability, PK and PD effects of orally administered AZD8529 after single ascending doses
- Trial name
- SAD (NCT00755378)
- Testing
- AZD8529
- Where
- United States
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Autoimmune Diseases, Multiple Sclerosis
First-in-Human Trial in Healthy Adult Volunteers to Evaluate Safety, Tolerability and PK of LAPIX Study Drug; LPX-TI641
A Phase I First-in-Human, Randomized, Double-Blind, Placebo-Controlled Study in Healthy Adult Volunteers to Evaluate Safety, Tolerability, and Pharmacokinetics after Single and Multiple Oral Dose of LPX-TI641.
- Trial name
- NCT05853835
- Testing
- LPX-TI641
- Where
- 2 sites in United States, Jordan
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- LAPIX Therapeutics Inc.
Healthy Subjects
Evaluate Retention of an Orally Administered Device Using Gamma Scintigraphy Study 2
Single usage, open label study in up to 40 adult healthy males. Eligible subjects will receive a single usage of the investigational or commercial device.
- Trial name
- NCT00780286
- Testing
- Polymer based lubricating liquid, Moi-Stir
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Procter and Gamble